LBA69 - Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial

A.M Arance,H Gogas,B Dreno,K.T Flaherty,L Demidov,D Stroyakovskiy,Z Eroglu,P.F Ferrucci,J Pigozzo,P Rutkowski,J Mackiewicz,I Rooney,A Voulgari,S Troutman,B Pitcher,Y Yan,J.M.G Larkin

doi:10.1093/annonc/mdz394.066

LBA69 - Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial

A.M Arance, H Gogas + Show 15 more

Open Access

https://doi.org/10.1093/annonc/mdz394.066

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2019
Citations: 20	License type: publisher-specific-oa

Affiliation: National and Kapodistrian University of Athens, Massachusetts General Hospital, Moscow City Oncology Hospital №62, Moffitt Cancer Center, Istituto Oncologico Veneto, The Maria Sklodowska-Curie National Research Institute of Oncology, Poznan University of Medical Sciences, Genentech, Roche (United Kingdom), Roche (Canada), Royal Marsden Hospital

#Research Grant #Stock Options + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

LBA69 - Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.